Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Brief Report titled “Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma,”1 published online March 25, 2021, a grant from the New York University’s Specialized Program of Research Excellence in Melanoma was omitted from the Funding/Support section. This article has been corrected online.
Error in Funding/Support. JAMA Oncol. 2021;7(5):785. doi:10.1001/jamaoncol.2021.1616
Coronavirus Resource Center